List of Revvity Signals Customers
Revvity, Inc. (ex Perkinelmer, Inc.)
77 4th Avenue,
Waltham, 2451, MA,
United States
Waltham, 2451, MA,
United States
1 781-663-6900
Professional Services
11000
$2.9B
Since 2010, our global team of researchers has been studying Revvity Signals customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Revvity Signals for Clinical Trial Management, Laboratory Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Revvity Signals for Clinical Trial Management, Laboratory Management include: Eli Lilly, a United States based Life Sciences organisation with 50605 employees and revenues of $65.18 billion, MilliporeSigma, a United States based Life Sciences organisation with 28000 employees and revenues of $7.00 billion, Camurus, a Sweden based Life Sciences organisation with 250 employees and revenues of $66.0 million, SK Life Science, a United States based Life Sciences organisation with 350 employees and revenues of $55.0 million, Axxam, a Italy based Life Sciences organisation with 200 employees and revenues of $32.0 million and many others.
Contact us if you need a completed and verified list of companies using Revvity Signals, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Revvity Signals customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Axxam | Life Sciences | 200 | $32M | Italy | Revvity | Revvity Signals | Clinical Trial Management,Laboratory Management | 2025 | n/a |
In 2025, Axxam implemented Revvity Signals to digitalize experimental records, aligning the project with the Clinical Trial Management,Laboratory Management application category. Axxam is a Milan headquartered contract research organization with approximately 200 employees and almost 120 scientists focused on early drug discovery, and the deployment centered on Revvity Signals Signals Notebook as a cloud-native, validation-ready electronic laboratory notebook. The rollout prioritized data integrity and compliance with existing quality frameworks already in place at Axxam.
Implementation included collaborative configuration work led by Revvity Signals with weekly working sessions that engaged representatives from 12 distinct internal groups including chemists, biologists, and data sciences. Teams analyzed more than 3000 historical paper notebooks to identify essential data elements and then developed standardized templates and dropdown-driven fields to improve traceability and reduce entry variation. Administrators were trained to create and modify templates, and 115 users across 12 departments were onboarded to Signals Notebook for routine experiment capture and archival.
Axxam’s Revvity Signals deployment leveraged native Revvity Signals components rather than bespoke third party integrations, configuring core modules such as ChemDraw for chemical communication, Inventory for real-time materials visibility, Task and Request workflows for intergroup collaboration, and an Instrumentation Database to link protocols with specific lab instruments. Operational coverage extended across functional groups including Compound Management, Cell Factory teams, and biology groups of more than 110 scientists, and the ELN enabled creation of client-ready PDFs and searchable archives for closed projects. The cloud-native Signals Notebook supported rapid integration of new facilities and made experimental data mobile across Axxam’s global facilities.
Governance and process changes reinforced existing quality systems, building on Axxam’s GLP-oriented controls established in 2006 and its ISO 9001 and ISO 27001 certifications achieved in July 2024. Signals Notebook was configured to support audit trails, data integrity controls, and standardized workflows that extended quality oversight beyond the laboratory into compound preparation and other service functions. Training, templating, and role-based administration were emphasized to sustain ongoing use, and the implementation narrative centers on structural improvements to data capture, traceability, and compliance rather than quantitative performance claims.
|
 |
Camurus | Life Sciences | 250 | $66M | Sweden | Revvity | Revvity Signals | Clinical Trial Management,Laboratory Management | 2023 | n/a |
In 2023 Camurus implemented Revvity Signals as its electronic lab documentation platform within the Clinical Trial Management,Laboratory Management application category. The deployment targeted Camurus’s R&D organization based in Lund, Sweden, and was positioned to replace manual, paper based lab records and fragmented document workflows across formulation and analytical groups. Camurus provisioned approximately 40 user licenses for Revvity Signals and framed the rollout to serve scientists working on FluidCrystal drug delivery programs and related late stage development activities.
The implementation centered on Signals Notebook capabilities inside Revvity Signals, including structured data capture, template management with table and form design, and integrated document handling for embedded Word, Excel, and PowerPoint content. Configuration emphasized Google like search performance and social collaboration features such as in platform chat and notifications to accelerate experiment discovery and cross team visibility. The cloud native SaaS architecture reduced onboarding friction, enabling quick uptake with minimal formal training and no recorded post implementation support engagements from the vendor.
Integrations were a procurement and adoption focal point, the selection team cited deep embedding with Microsoft Excel, Word, and PowerPoint as a primary differentiator, and the platform’s APIs and interfaces were used to connect Signals Notebook to other elements of Camurus’s technology stack. Operational coverage concentrated on laboratory execution and R&D decision support, with linked experiment workflows enabling formulation scientists to start experiments and pass structured analytical results back to analytical scientists in chained records. Access control was governed by the platform’s rule based permissions model to support internal teams and external CRO interactions.
Governance and process changes accompanied the technical deployment, teams reworked experiment planning, approval, and reporting routines to eliminate paper routing and fragmented archives, and new hires reported faster onboarding into documented lab practices. Subjective outcomes documented by Camurus leadership included improved findability of experimental data, improved collaboration across formulation and analytical functions, and a perception of rapid value capture from a relatively small procurement and training effort.
|
 |
Eli Lilly | Life Sciences | 50605 | $65.2B | United States | Revvity | Revvity Signals | Clinical Trial Management,Laboratory Management | 2025 | n/a |
In 2025 Eli Lilly deployed Revvity Signals to standardize R&D data management and support molecule registration workflows. Eli Lilly deployed Revvity Signals for Clinical Trial Management,Laboratory Management to enable collaborative research notebooks, automate routine experiment actions, and centralize compliance controls across its research organization. The implementation was led by R&D IT and research informatics stakeholders and emphasized integration with existing research workflows rather than replacing specific prior platforms.
The deployment made explicit use of Signals Notebook capabilities, including REST APIs, external actions, and external notifications to automate sample and molecule registration processes. Revvity Signals was configured to allow researchers to initiate external actions from within the notebook interface, with options for manual approval to preserve user oversight. Dashboards built with Power BI and KNIME were implemented to surface unsigned experiments, unedited data, and user activity, supporting operational monitoring and productivity tracking.
Architecturally the integration architecture centered on a versioned API layer, enabling programmatic replication of interface actions and minimizing disruption to downstream consumers when the product updated. Data flows routed selected experiment metadata from Revvity Signals into Eli Lilly’s proprietary registration database, and external notifications were used to trigger downstream ETL and analytics processes. The integration framework documented API usage patterns and external action contracts to maintain consistent behavior across automated workflows and reporting tools.
Governance and rollout followed a GxP-aware, phased approach, aligning integration schedules with deferred and post-deferred release cycles for Signals Notebook. Eli Lilly defined clear roles and responsibilities for internal and external teams, enforced least-privilege access for APIs, and instituted regular auditing and validation activities to ensure ongoing compliance. Testing and validation gates were emphasized during major updates, while business-specific configurations and integrations were sequenced between major releases.
Outcomes reported by the presenting teams included streamlined compliance workflows, elevated collaboration through shared notebook standards, and improved research efficiency by automating routine registration and data transfer tasks. Revvity Signals served as a central platform connecting laboratory data capture to registration and analytics functions, enabling Eli Lilly to balance automation with manual controls in regulated research environments.
|
 |
MilliporeSigma | Life Sciences | 28000 | $7.0B | United States | Revvity | Revvity Signals | Clinical Trial Management,Laboratory Management | 2025 | n/a |
In 2025, Millipore Sigma deployed Revvity Signals to establish a digital process twin capability within its research workflows, aligning the company with the Clinical Trial Management,Laboratory Management application category. The implementation targets experiment design and execution, centralizing experimental building blocks and metadata to enable reproducible, shareable workflows across distributed research teams.
The Revvity Signals deployment implements a modular library of reusable experimental building blocks, a drag and drop workflow editor, machine-readable metadata capture, a simulation or in-silico modeling capability, and real-time monitoring dashboards. Revvity Signals Notebook functions as the electronic lab notebook integration point that consolidates digital workflows into a single data repository, enabling the creation and orchestration of digital process twins and automated handoffs between experimental steps.
Integrations instrumental to the implementation include explicit linkage to electronic lab notebooks such as Revvity Signals Notebook, streaming inputs from laboratory equipment and environmental condition feeds, and human interaction event capture within experiment execution logs. Operational coverage is focused on laboratory research teams and cross-functional scientific groups that require standardized protocol execution and shared workflow artifacts for collaboration and reproducibility.
Governance changes emphasized standardized workflow templates, enforced metadata schemas, and process controls to ensure consistent data capture and experiment reproducibility across the organization. The program placed digital process twins at the center of experimental governance, embedding workflows into routine lab practice and enabling teams to simulate and validate protocols before physical runs, while retaining audit trails appropriate for regulated research settings.
Observed outcomes reported by Millipore Sigma include accelerated experimental timescales by up to 75 percent, enhanced data quality through enriched metadata and real-time monitoring, and improved collaboration and reproducibility through standardized processes. Revvity Signals is presented as the platform unifying Millipore Sigma experiment design, and the implementation underscores the relationship Millipore Sigma Revvity Signals Clinical Trial Management,Laboratory Management experiment design and execution.
|
 |
SK Life Science | Life Sciences | 350 | $55M | United States | Revvity | Revvity Signals | Clinical Trial Management,Laboratory Management | 2025 | n/a |
In 2025, SK Life Science implemented Revvity Signals, deploying the Signals Notebook electronic lab notebook as a cloud native informatics platform aligned with Clinical Trial Management,Laboratory Management. SK Life Science Labs functions as a compact discovery unit with roughly 40 scientists collaborating with nearly a dozen contract research organizations, creating a requirement for secure external collaboration and managed permissions. The deployment used a SaaS secure workspace architecture to centralize experimental records, metadata, and inventory information for discovery workflows.
Signals Notebook was configured with standardized templates and protocol driven data capture to enforce naming conventions and consistent metadata across internal teams and CROs. The implementation included sample and compound registration workflows that generate registration IDs, automated scripts to update protein batch inventory and physical locations, and permission controls that allow CRO staff to record experiments directly in the platform. The team used application programming interface calls to orchestrate experiment initiation, experiment status updates, and inventory synchronization with external systems, consolidating scientific data inside the Revvity Signals Signals Notebook environment.
Revvity Signals Signals Notebook was integrated natively with Spotfire to populate a management dashboard that links usernames, experiments, and experimental status, the dashboard updating automatically as experiments are performed. API integrations fetch metadata and experimental status into Spotfire visualizations, and records include hyperlinks back to full ELN entries for compliance and auditability. The deployment also recorded interactions with an external compound registry as part of the sample lifecycle, preserving traceability from CRO submission through registration and storage.
Governance and process changes established templated data entry, enforced file naming conventions, and role based access policies to standardize workflows across all CRO partners. These controls reduced errors and back and forth corrections by ensuring required fields and protocols are validated at entry in Signals Notebook.
Outcomes explicitly reported include accelerating CRO workflows from days to minutes and improvements in efficiency, traceability, communication, inventory management, and operational visibility via Spotfire dashboards. The combined Clinical Trial Management,Laboratory Management implementation centralized experimental records, made protein inventories discoverable to internal and external researchers, and provided senior leadership near real time visibility into R and D progress.
|
Showing 1 to 5 of 5 entries
Buyer Intent: Companies Evaluating Revvity Signals
ARTW Buyer Intent uncovers actionable customer signals, identifying software buyers actively evaluating Revvity Signals. Gain ongoing access to real-time prospects and uncover hidden opportunities. Companies Actively Evaluating Revvity Signals for Clinical Trial Management, Laboratory Management include:
- Market Gain, a United States based Retail organization with 10 Employees
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated |
|---|---|---|---|---|---|---|
 |
Market Gain | Retail | 10 | $1M | United States | 2026-03-13 |
FAQ - APPS RUN THE WORLD Revvity Signals Coverage
Revvity Signals is a Clinical Trial Management, Laboratory Management solution from Revvity.
Companies worldwide use Revvity Signals, from small firms to large enterprises across 21+ industries.
Organizations such as Eli Lilly, MilliporeSigma, Camurus, SK Life Science and Axxam are recorded users of
Revvity Signals for Clinical Trial Management, Laboratory Management.
Companies using Revvity Signals are most concentrated in Life Sciences, with adoption spanning over 21 industries.
Companies using Revvity Signals are most concentrated in United States, Sweden and Italy, with adoption tracked across 195 countries worldwide. This global distribution highlights the popularity of Revvity Signals across Americas, EMEA, and APAC.
Companies using Revvity Signals range from small businesses with 0-100 employees - 0%, to mid-sized firms with 101-1,000 employees - 60%, large organizations with 1,001-10,000 employees - 0%, and global enterprises with 10,000+ employees - 40%.
Customers of Revvity Signals include firms across all revenue levels — from $0-100M, to $101M-$1B, $1B-$10B, and $10B+ global corporations.
Contact APPS RUN THE WORLD to access the full verified Revvity Signals customer database with detailed Firmographics such as industry, geography, revenue, and employee breakdowns as well as key decision makers in charge of Clinical Trial Management, Laboratory Management.